BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31610665)

  • 21. Metastatic Colorectal Cancer to the Peritoneum: Current Treatment Options.
    Vassos N; Piso P
    Curr Treat Options Oncol; 2018 Sep; 19(10):49. PubMed ID: 30173342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.
    Piso P; Stierstorfer K; Gerken M; Klinkhammer-Schalke M
    Int J Colorectal Dis; 2018 Nov; 33(11):1559-1567. PubMed ID: 30132068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.
    Ubink I; van Eden WJ; Snaebjornsson P; Kok NFM; van Kuik J; van Grevenstein WMU; Laclé MM; Sanders J; Fijneman RJA; Elias SG; Borel Rinkes IHM; Aalbers AGJ; Kranenburg O
    Br J Surg; 2018 Jan; 105(2):e204-e211. PubMed ID: 29341165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
    J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
    Bushati M; Rovers KP; Sommariva A; Sugarbaker PH; Morris DL; Yonemura Y; Quadros CA; Somashekhar SP; Ceelen W; Dubé P; Li Y; Verwaal VJ; Glehen O; Piso P; Spiliotis J; Teo MCC; González-Moreno S; Cashin PH; Lehmann K; Deraco M; Moran B; de Hingh IHJT
    Eur J Surg Oncol; 2018 Dec; 44(12):1942-1948. PubMed ID: 30075978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
    Arjona-Sanchez A; Rodriguez-Ortiz L; Baratti D; Schneider MA; Gutiérrez-Calvo A; García-Fadrique A; Tuynman JB; Cascales-Campos PA; Martín VC; Morales R; Salti GI; Arteaga X; Pacheco D; Alonso-Gomez J; Yalkin O; Villarejo-Campos P; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Rufian-Peña S; Briceño J
    Ann Surg Oncol; 2019 Aug; 26(8):2595-2604. PubMed ID: 31111351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
    Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
    World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
    Horvath P; Beckert S; Königsrainer A; Nadalin S; Königsrainer I
    J Visc Surg; 2019 Dec; 156(6):475-484. PubMed ID: 31324533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
    Cortes-Guiral D; Elias D; Cascales-Campos PA; Badía Yébenes A; Guijo Castellano I; León Carbonero AI; Martín Valadés JI; Garcia-Foncillas J; Garcia-Olmo D
    World J Gastroenterol; 2017 Jan; 23(3):377-381. PubMed ID: 28210074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of colorectal cancer patients at high risk of peritoneal metastases.
    Shariff U; Seretis C; Youssef H
    J BUON; 2015 May; 20 Suppl 1():S71-9. PubMed ID: 26051336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O;
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer.
    Glockzin G; Ghali N; Lang SA; Schlitt HJ; Piso P
    J Surg Oncol; 2009 Sep; 100(4):306-10. PubMed ID: 19697436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Verwaal VJ; Bruin S; Boot H; van Slooten G; van Tinteren H
    Ann Surg Oncol; 2008 Sep; 15(9):2426-32. PubMed ID: 18521686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy.
    Pletcher E; Gleeson E; Labow D
    Surg Clin North Am; 2020 Jun; 100(3):589-613. PubMed ID: 32402303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases.
    Simkens GA; Razenberg LG; Lemmens VE; Rutten HJ; Creemers GJ; de Hingh IH
    Eur J Surg Oncol; 2016 Jun; 42(6):794-800. PubMed ID: 27055946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer.
    Behrenbruch C; Hollande F; Thomson B; Michael M; Warrier SK; Lynch C; Heriot A
    ANZ J Surg; 2017 Sep; 87(9):665-670. PubMed ID: 28664645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Cravioto-Villanueva A; Cavazos M; Luna-Perez P; Martinez-Gomez H; Ramirez ML; Solorzano J; Montiel H; Esquivel J
    Surg Today; 2016 Aug; 46(8):979-84. PubMed ID: 27138212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.